Wnt/β-catenin Activation Promotes Prostate Tumor Progression in a Mouse Model
Overview
Authors
Affiliations
Our previous studies have found that activation of Wnt/β-catenin signaling resulted in mouse prostatic intraepithelial neoplasia (mPIN). In the large probasin promoter directed SV40-large T-antigen (LPB-Tag) expressing mouse prostate, mPIN forms with rare areas of adenocarcinoma. Combining expression of both Wnt-signaling and Tag expression in the mouse prostate, we have studied the role of Wnt/β-catenin signaling in the progression from mPIN to adenocarcinoma. Our results show that the prostates of mice expressing Tag alone or nuclear β-catenin alone developed mPIN, whereas the activation of both Tag and the Wnt/β-catenin pathway resulted in invasive prostate adenocarcinoma. Furthermore, Foxa2, a forkhead transcription factor, was induced by active Wnt/β-catenin signaling, and the expression of Foxa2 was associated with the invasive phenotype in the primary prostate cancer. In the LPB-Tag/dominant active (DA) β-catenin prostates, MMP7, a Wnt/β-catenin target gene, was upregulated. Furthermore, we also assessed AR and AR signaling pathway in these LPB-Tag/DA β-catenin mice. Although β-catenin is a well-known AR co-activator in vitro, our study provides strong in vivo evidences indicating that both AR protein and the AR pathway were downregulated in the prostate of LPB-Tag/DA β-catenin mice. Histological analysis shows that prostate sections derived from the LPB-Tag/DA β-catenin mice display neuroendocrine differentiation (NED), but NE cancer does not develop. Together, our findings indicate that Wnt/β-catenin signaling has an important role in the progression of mPIN to prostate adenocarcinoma.
Wang S, Xie D, Yue H, Li G, Jiang B, Gao Y Biomedicines. 2025; 13(2).
PMID: 40002717 PMC: 11853330. DOI: 10.3390/biomedicines13020304.
Kaushal J, Takkar S, Batra S, Siddiqui J Cancer Lett. 2024; 593:216954.
PMID: 38735382 PMC: 11799897. DOI: 10.1016/j.canlet.2024.216954.
Liu X, Yan C, Chang C, Meng F, Shen W, Wang S Adv Sci (Weinh). 2023; 10(35):e2304521.
PMID: 37875418 PMC: 10724393. DOI: 10.1002/advs.202304521.
Varisli L, Tolan V, Cen J, Vlahopoulos S, Cen O Oncol Res. 2023; 30(3):137-155.
PMID: 37305018 PMC: 10208071. DOI: 10.32604/or.2022.026074.
Serttas R, Erdogan S Med Oncol. 2023; 40(7):194.
PMID: 37264204 DOI: 10.1007/s12032-023-02062-1.